All In Biotech

Drug Trial Radar · NCT06278948

Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma

Randomized Controlled Investigator Blinded Comparative Study of the Efficacy and Tolerability of Test Product Versus Cysteamine 5% in the Treatment of Facial Epidermal Melasma Over 4 Months

Last checked: Nov 19, 2026Latest source record: Feb 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

140

Planned (sponsor's estimate)

Start

Oct 6, 2023

Primary completion

Jun 2024

Study completion Jun 2024

Sponsor

Sponsor type
Industry
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This interventional, randomized, investigator blinded, controlled study conducted in one centre consists in a 4-month evaluation period within the same season avoiding sunny season on 140 subjects with facial epidermal melasma.

Conditions

  • Melasma

Interventions

  • Group TPOther

    Application full face, twice daily, in the morning and at bedtime for 4 months

  • Group CYSDrug

    Application short contact, of thin layer once daily at bedtime for 4 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in mMASI scoringTime frame: from baseline to Day112
  2. change in Investigator's Global Assessment (IGA)Time frame: from baseline to Day112

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MS Clinical Research Pvt. Ltd

    Bangalore, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.